Augmentation by interleukins of the antibody response to a conjugate vaccine against Haemophilus influenzae b.
Interleukins have been recognized as potential adjuvants for use during vaccination. The immunogenicity of some poorly immunogenic bacterial capsular polysaccharides have been improved by conjugation to a protein carrier. Augmentation of the immune response to these glycoconjugates, however, may be realized in the presence of interleukins. The antibody response to one such vaccine which comprises a oligosaccharide derived from the capsule of Haemophilus influenzae type b coupled to CRM197 (HbOC) can be augmented in this manner. A suboptimal dose (0.1 microgram) of HbOC and varying concentrations of IL-1 alpha or IL-1 beta (10(2) - 5 x 10(5) U) were injected intramuscularly at 0 and 2 weeks into Swiss Webster mice. Vaccines were also formulated with and without aluminum phosphate. Antibody to the oligosaccharide was determined by Farr assay. In 3/3 experiments, IL-1 alpha enhanced primary and secondary antibody responses whereas with IL-1 beta, only a slight increase in the primary antibody response was seen but enhanced secondary responses were observed. Thus, IL-1 alpha and to some extent IL-1 beta enhanced the primary and secondary antibody responses to a glycoconjugate vaccine.
Bixler
G S
GS
Praxis Biologics, Inc., Rochester, New York 14623.
Pillai
S
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D006001:Glycoconjugates / Q000276:immunology; D006193:Haemophilus influenzae / Q000276:immunology*; D007375:Interleukin-1 / Q000008:administration & dosage*; D051379:Mice
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D006001:Glycoconjugates; D007375:Interleukin-1